Synthesis and Evaluation of Triazolyl Dihydropyrimidines as Potential Anticancer Agents

Rajanna Ajumeera¹, Ganapathi Thipparapu¹, Shireesha Boyapati², Bharath Singh Padya¹ and Vijayalaxmi Venkatesan¹
¹Division of stem Cell Research, National Institute of Nutrition, Tanaka, Hyderabad, Telangana, India
²Department of Pharmaceutical Chemistry, Telangana University, Dichpally, Telangana, India

Correspondence: Rajanna Ajumeera, Division of stem Cell Research, National Institute of Nutrition, Tanaka, Hyderabad, Telangana, India.

Received: September 17, 2018 Accepted: November 1, 2018 Online Published: November 8, 2018
doi:10.5539/ijc.v10n4p18 URL: https://doi.org/10.5539/ijc.v10n4p18

Abstract

Novel N – triazolyl 3(a-f) and O-triazolyl (4a-f) derivatives of 4, 6-diaryl-1, 4-dihydropyrimidines were synthesized through manich reaction. All compounds were characterized by physical and spectral data. These compounds were screened for in vitro efficiency in human breast cancer cell (MCF-7&MDA-MB-231) lines and found to have very good anti-proliferative activity. Among all compounds of 4b, 3e, 4e endowed with lesser respective IC₅₀ values of 31.94, 55.73, 55.03 μM in MCF-7 cells and 41.50, 35.28, 32.06 μM in MDA-MB 231 cells by MTT assay. In further studies, Compounds 4b, 3e, 4e were found to arrest cell growth at S phase in MCF-7 cells. In MDA-MB 231 cells, 4b, 4e were found to arrest the cells in S phase, and compound 3e found to arrest G2/M phase when compared to the standard drug tamoxifen, arrested S phase in MCF-7 cells and G0/G1 phase in MDA-MB 231 cells.

Keywords: dihydropyrimidines, triazoles, anticancer activity, cell cycle, breast cancer cells, MTT assay

1. Introduction:

Pyrimidines were nitrogen compounds, discovered in 1893 and are cyclic amines. It is also known as m-diazine (or) 1, 3-diazine and got the recognition as parent nucleus of large group of heterocyclic compounds. The reduced pyrimidines i.e. dihydropyrimidines (DHPM) is also an interesting heterocyclic ring, that was found to possess a vital role in numerous biological processes as it is the core nucleus of the endogenous molecules like nucleic acids, co-enzymes, several vitamins, purines and liposaccharides. It has been reported for various biological activities like antibacterial (Sangaraiah, et al., 2012), antifungal (Rumi, et al., 2013), antiviral (Hockova, et al., 2003, Breault, et al., 2003), anticancer (Sosnicki, et al., 2014), antihypertensive (Chikhale, et al., 2009) with calcium channel blocking and dihydrofolate reductase inhibition. In addition, these compounds emerged as potential α₁-adrenergic antagonists (Schneider, et al., 2003), vasodilators (Cernecka, et al., 2012), antiatherosclerotic (Dobrusin, et al., 2001), antiadiabetic (Lauro, et al., 2010), antiplatelet aggregation (Bruno, et al., 2001) and neuropeptide antagonists (Chikhale, et al., 2009). The chemistry of Pyrimidines has been extensively studied, since the Pyrimidine is a symmetrical molecule about the line passing through C₂ and C₅, the N₁ and N₃ positions are equivalent and so are C₄ and C₆. When a -OH or -NH₂ group is present at the 2, 4 or 6 position then there is a keto-enol or amino-imino tautomerism existed with o xo and imino forms.

The other nitrogen based heterocyclic nucleus 1,2,4-triazole was associated with diverse range of pharmacological activities such as analgesic, antiinflammatory, antiasthmatic, anticholinergic, antihypersensitive, antibacterial, antifungal and diuretic activity (Birendra et al, 1984, Kothari et al, 1980, Sengupta & Misra, 1981, Sarmah & Bahel, 1982). Mannich bases are well known for their medicinal values such as dynamic chemotherapeutic agent (Anticancer, antibacterial, antifungal, anthelmintic, anti-HIV, antiviral, antitubercular & antimarial activities), anti-inflammatory, anticonvulsant, analgesic & antipsychotic activities (Koksal, et al., 2007; Vashishtha, et al., 2004, Sriram, et al., 2009; Mulla, et al., 2011). The biological data of both the heterocycles provoked us to synthesize some new dihydropyrimidine derivatives containing 1,2,4-triazole ring.

In the present investigation, based on the structural significance of dihydropyrimidines and mannich bases, we designed and synthesized mannich bases of dihydropyrimidinone with regioselectivity. Mannich bases were synthesized by reacting DHPR with secondary amine and formaldehyde in the presence and absence of catalytic amount of potassium carbonate to get O- and N-mannich bases respectively. DHPM were synthesized from chalcones containing different
substitutions on the both aromatic rings. Different secondary amines were used for the synthesis of manich bases such as aliphatic, aromatic and heterocyclic amines (Bandgar, et al., 2010; Trivedi, et al., 2008; Shah, et al., 2010; Pandeya, et al., 2000). The synthesized compounds (3a-3f & 4a-4f) were evaluated for anti-cancer activity *in vitro* in human breast cancer cell (MCF-7 & MDA-MB-231) lines. The toxicity of these derivatives was predicted by using *in silico* methods (Ganapathi et al, 2016).

2. Synthesis of Dihydropyrimidine Derivatives

Scheme:

![chemical structure diagram]

2. Chemistry

All the chemicals were purchased from Sd-Fine chemicals ltd, Ranbaxy chemicals ltd, Loba Chemicals ltd and Qualigens chemicals ltd. All the solvents used were of laboratory grade. All reactions were monitored by thin layer chromatography (TLC) on precoated silica gel 60 F254 (mesh); spots were visualized with UV light. Merck silica gel (100–200 mesh; Merck, Germany) was used for chromatography. All the synthesized compounds were purified by recrystallization (or) column chromatography. Melting points were determined on open capillary method and were uncorrected. IR spectra were recorded on a Perkin-Elmer FT-IR 240-C spectro photometer using KBr optics (Perkin-Elmer. USA). $^1$H-NMR spectra were recorded on Gemini Varian (Varian, USA) 200 MHz, Bruker (Bruker
2.1 Synthesis of Chalcones

A mixture of 22 gm of NaOH in 200 ml of water and 100 ml of rectified spirit in a 500 ml bolt head flask was provided with a magnetic stirrer. The flask was immersed in a bath of crushed ice, 0.43 mol of freshly distilled acetophenone was added while stirring and then 0.43 mole of pure benzaldehydes was added. The temperature of the mixture was kept at about 5°C (limits are 0-5°C) and stirred vigorously until the mixture was so thick that stirring is no longer effective (2-3 h). The reaction was monitored by TLC. After completion of the reaction, stirrer was removed, and the reaction mixture was kept in ice chest or refrigerator overnight. Thus, obtained product was filtered and washed with cold water until the washings were neutral to litmus and then with 20 ml of ice-cold rectified spirit and dried and re-crystallized from chloroform.

2.2 Synthesis of Dihydropyrimidine -2-one (2)

A mixture of 0.01 mole of chalcone, 0.01 mole of urea and 1gm of KOH were dissolved in minimum amount of ethanol in a glass beaker and were subjected to microwave irradiation at 80% power with the intervals of 10 seconds each. The reaction was monitored by TLC. After completion of the reaction, the contents were cooled to room temperature and poured into ice cold water (50 ml) while stirring. The solid thus separated was filtered, washed with portions of cold water and dried. It was purified by recrystallization from ethanol to give a pure compound.

2.3 Synthesis of N-Mannich Dihydropyrimidine Derivatives

Dihydropyrimidine (2, 0.005 mole) was dissolved in minimum amount of DMSO in a glass beaker and 37% HCHO (0.01 mole), and appropriate secondary amine (0.005 mol) was added. The reaction mixture was exposed to microwave irradiation at 480 micro power with the intervals of 1 minute each. The reaction progress was monitored by TLC and the mixture was kept at refrigerator for 48h, filtered the separated product, washed with small portions of cold water and dried. The crude product was purified by recrystallization from Pet. Ether: Chloroform (1:1 mixture).

2.4 Synthesis of O-Mannich Dihydropyrimidine Derivatives

Dihydropyrimidine (2, 0.005 mole) was dissolved in minimum amount of DMSO in a glass beaker and 37% HCHO (0.01 mole), anhydrous potassium carbonate (1.0g), appropriate secondary amine (0.005 mol) was added and this reaction mixture was exposed to microwave irradiation at 80% power with the intervals of 20 seconds each. The reaction progress was monitored by TLC and the mixture was kept at refrigerator for 48h, filtered the separated product, washed with small portions of cold water and dried. The crude product was purified by recrystallization from Pet. Ether: Chloroform (1:1 mixture).

3. Biological Activity

3.1 Cell Culture

The human breast cancer (MCF-7 &MDA MB231) cells were obtained from NCCS, Pune, India. Both cells lines were cultured in DMEM high glucose (Gibco, USA) supplemented 10% fetal bivine serum (Gibco, USA) in a humidify incubator 37°C incubator containing 5% CO₂ environment with 0.5% Penicillin-streptomycin (Sigma, USA). The medium was exchanged every 2 days with fresh medium to maintain cell activity.

3.2 MTT Assay

Breast cancers (MCF-7 &MDA MB231) cells were plated in density of 5600 cells/100 μl and incubated in 96-well plate. The cells were exposed to various concentrations of dihydropyrimidine derivatives for 24 hours. Sensitivity of the agents were determined by the MTT assay (Promega, Mannheim, Germany) following the manufacturers’ instructions in quadruplicates using a photometer at the wavelength of 490 nm. IC₅₀ values were determined from the growth inhibition curve.

3.3 Cell Cycle Analysis

Human breast cancers (MCF-7 &MDA MB231) cells (1 × 10⁵ cells/well) were seeded in 6-well plates. After 24 h, the medium was replaced by fresh culture medium with IC50 concentrations of dihydropyrimidine derivatives (3a-f &4a-f). The cell cycle assay was performed and analyzed by measuring the amount of propidium iodide (PI)-labeled DNA in ethanol-fixed cells. In brief, cells will be treated for 24 h, harvested by trypsinization and fixed with chilled 70% ethanol. Cells were stained for total DNA content with PI (5mg/mL) staining buffer has RNase enzyme according to the manufacturer’s instructions. The percentages of cells in different phases Go-G1, S and G2-M were observed with flow cytometer, BD Aria II instrument and analyzed by Mod Fit software.
4. Result and Discussion

The present study investigated anti-proliferative activity cell cycle distribution pattern of dihydropyrimidine derivatives in human breast cancer (MCF-7 & MDA-MB-231) cell lines using *in vitro* model. It is important to select the appropriate concentrations for the treatment to find optimum concentrations. Here, we have treated cells with wide range of concentrations and optimized IC$_{50}$ concentrations of dihydropyrimidine derivatives of 3a-3f & 4a-4f were fall in the range of 31.94-101.94 µM in MCF-7 cells as well as 32.06-98.04 in MDA-MB-231 cells (Table 1) of human breast cancer cell lines. Among all the compounds chloro and dichloro substitutions of 4b, 4e and 3e were shown lesser IC$_{50}$ concentrations were 31.94, 55.03 and 55.73 µM in MCF-7 cell line, whereas 41.50, 32.06 and 35.28µM in MDA-MB-231 cells. Here the both the cell lines were chemo sensitive to the dihydropyrimidine derivatives. But, triple negative and ER negative cell line of MDA-MB-231 were relatively more chemo sensitive than MCF-7 cells.

Table 1. The IC50 concentrations of dihydropyrimidine derivatives (3a-f &4a-f) in human breast cancer (MCF-7&MDA-MB 231) cell lines were estimated MTT assay

<table>
<thead>
<tr>
<th>Sample</th>
<th>MCF-7 Cells IC50µM</th>
<th>MDA-MB 231 IC50µM</th>
</tr>
</thead>
<tbody>
<tr>
<td>3a</td>
<td>104.94±0.47</td>
<td>94.31±0.27</td>
</tr>
<tr>
<td>3b</td>
<td>72.94±0.22</td>
<td>48.54±0.28</td>
</tr>
<tr>
<td>3c</td>
<td>73.03±0.21</td>
<td>85.05±0.21</td>
</tr>
<tr>
<td>3d</td>
<td>75.05±0.19</td>
<td>73.94±0.18</td>
</tr>
<tr>
<td>3e</td>
<td>55.73±0.16</td>
<td>35.28±0.19</td>
</tr>
<tr>
<td>3f</td>
<td>73.94±0.25</td>
<td>40.62±0.19</td>
</tr>
<tr>
<td>4a</td>
<td>95.04±0.48</td>
<td>98.04±0.38</td>
</tr>
<tr>
<td>4b</td>
<td>31.94±0.12</td>
<td>41.50±0.26</td>
</tr>
<tr>
<td>4c</td>
<td>80.64±0.34</td>
<td>90.45±0.24</td>
</tr>
<tr>
<td>4d</td>
<td>79.39±0.22</td>
<td>92.24±0.28</td>
</tr>
<tr>
<td>4e</td>
<td>55.03±0.27</td>
<td>32.06±0.22</td>
</tr>
<tr>
<td>4f</td>
<td>73.51±0.34</td>
<td>43.96±0.19</td>
</tr>
<tr>
<td>Tamoxifen</td>
<td>19.00±0.16</td>
<td>23.46±0.21</td>
</tr>
</tbody>
</table>

However, these three selected compounds (4b, 4e & 3e) were further studied their cell cycle regulation pattern in both breast cancer cells. Cell cycle progression of cell cycle regulation is a set of coordinated events happen in completion of one complete cell cycle. The cells distributed in to four major phases; G1 (growth phase 1), S (DNA synthesis phase), G2 (growth phase 2) and M(mitosis), which were functioning to integrate environment sensing signalling pathways with cell growth and proliferation (Ge´ rard, C, *et al.*, 2014). Most of anticancer drugs disturb proliferation cycle of tumour and inhibit the cell cycle events, which activate checkpoints, arrest cells and induce apoptosis (Chan, K.S, *et al.*, 2012). Here, we have studied the cell cycle regulation pattern of selected compounds of 3e, 4e and 4b dihydropyrimidines with DNA binding agent propidium iodide dye. The cells were arrested in s phase 3e, 4e & 4b in MCF-7 cells (Figure 1A). Whereas 4e, 4b arrested cells in S phase and 3e arrested cells in G2-M phase in MDA-MB-231 cell line indicated N-mannich base of chloro substitution compound arrested cells in proliferation stage (synthesis phase), whereas, 3e arrested cells in G2/M (mitotic phase) and 4b and 4e were arrested cells in S phase of cell cycle events in MDA-MB 231 cells (Figure 1B). Indicates the chloro and dichloro substitution in dihydropyrimidine derivatives were restricting cell cycle progression in human breast cancer cells, whereas the standard drug tamoxifen has been arrested cells in G0/G1 phase in both the cell lines.
5. Spectral Data of Dihydropyrimidine Derivatives

5.1 4,6-Diphenyl-3-[(1H-[1,2,4]triazol-3-ylamino)-methyl]-3,4-dihydro-1H-pyrimidin-2-one (3a)
Yield: 43%; mp: 190-192°C; IR (KBr disc, cm⁻¹): 3269 (N-H Stretch), 2924 (Ar-H), 1596, 1494 (Ar C=O Stretch), 1652 (C=O Stretch), 1214 (C-N stretch); ¹H NMR (400 MHz, DMSO-D₆) δ 5.6 (d, 1H, pyrimidin CH), 5.9 (d,1H,pyrimidin C=CH), 8.9 (t, H, C-NH-C, pyrimidin), 4.9 (d, 2H, N-CH₃-N), 5.3-5.5 (s, 1H, Pyrimidine N-H), 7.0-7.6 (m, 10H, Ar-H), 7.9 (d, 1H, triazole CH), 8.1 (d, 1H, triazole NH); LC-MS: m/z 247.0 [M⁺+1].

5.2 4-(4-Chloro-phenyl)-6-phenyl-3-[(1H-[1,2,4]triazol-3-ylamino)-methyl]-3,4-dihydro-1H-pyrimidin-2-one (3b)
Yield: 45%; mp: 315-8°C; IR (KBr disc, cm⁻¹): 3258 (N-H Stretch), 2930 (Ar-H), 1591, 1488 (Ar C=C Stretch), 1649 (C=O Stretch), 1214 (C-N stretch), 1083 (C-Cl stretch); ¹H NMR (400 MHz, DMSO-D₆) 5.65 (d, 1H, pyrimidine CH), 5.9 (d,1H,pyrimidin C=CH), 8.9 (t, H, C-NH-C, pyrimidin), 4.9 (d, 2H, N-CH₃-N), 5.3-5.5 (s, 1H, Pyrimidine N-H), 7.0-7.6 (m, 9H, Ar-H), 7.9 (d,1H, triazole CH), 8.2 (d, 1H, triazole NH); LC-MS: m/z 382.0 [M⁺+2].

5.3 4-(4-Methoxy-phenyl)-6-phenyl-3-[(1H-[1,2,4]triazol-3-ylamino)-methyl]-3,4-dihydro-1H-pyrimidin-2-one (3c)
Yield: 42%; mp: 335-8°C; IR (KBr disc, cm⁻¹): 3252 (N-H Stretch), 2933 (Ar-H), 1589, 1487 (Ar C=C Stretch), 1654 (C=O Stretch), 1221 (C-N stretch), 1245, 1080 (C-O-C stretch); ¹H NMR (400 MHz, DMSO-D₆) 3.8 (s, 3H, O-CH₃), 5.5 (d,1H,pyrimidine CH), 5.8 (d,1H,pyrimidin C=CH), 8.9 (t, H, C-NH-C, pyrimidin), 4.9 (d, 2H, N-CH₂-N), 5.3 (s, 1H, Pyrimidine N-H), 7.0-7.6 (m, 9H, Ar-H), 7.9 (d,1H, triazole CH), 8.1 (d, 1H, triazole -NH); LC-MS: m/z 377.0 [M⁺+1].

5.4 6-(4-Chloro-phenyl)-4-phenyl-3-[(1H-[1,2,4]triazol-3-ylamino)-methyl]-3,4-dihydro-1H-pyrimidin-2-one (3d)
Yield: 49%; mp: 312-5°C; IR (KBr disc, cm⁻¹): 3248 (N-H Stretch), 2920 (Ar-H), 1577, 1458 (Ar C=C Stretch), 1639 (C=O Stretch), 1234 (C-N stretch), 1075 (C-Cl stretch); ¹H NMR (400 MHz, DMSO-D₆) 5.6 (d,1H,pyrimidine CH), 5.9 (d,1H,pyrimidin C=CH), 8.9 (t, H, C-NH-C, pyrimidin), 4.9 (d, 2H, N-CH₂-N), 5.2-5.3 (s, 1H, Pyrimidine N-H), 7.0-7.6 (m, 9H, Ar-H), 7.9 (d,1H, triazole CH), 8.1 (d, 1H, triazole NH); LC-MS: m/z 382.0 [M⁺+2].

5.5 4,6-Bis-(4-chloro-phenyl)-3-[(1H-[1,2,4]triazol-3-ylamino)-methyl]-3,4-dihydro-1H-pyrimidin-2-one (3e)
Yield: 48%; mp: 320-2°C; IR (KBr disc, cm⁻¹): 3238 (N-H Stretch), 2914 (Ar-H), 1566, 1448 (Ar C=C Stretch), 1633 (C=O Stretch), 1230 (C-N stretch), 1085, 1106 (C-Cl stretch); ¹H NMR (400 MHz, DMSO-D₆) 5.4 (d,1H,pyrimidine CH), 5.8 (d,1H,pyrimidin C=CH), 8.9 (t, H, C-NH-C, pyrimidin), 4.9 (d, 2H, N-CH₂-N), 5.2-5.3 (s, 1H, Pyrimidine N-H), 7.0-7.6 (m, 9H, Ar-H), 7.9 (d,1H, triazole CH), 8.3 (d, 1H, triazole NH); LC-MS: m/z 416.0 [M⁺+2].
5.6 6-(4-Chloro-phenyl)-4-(4-methoxy-phenyl)-3-[(1H-[1,2,4]triazol-3-ylamino)-methyl]-3,4-dihydro-1H-pyrimidin-2-one (3f)
Yield: 45%; mp: 338-40°C; IR (KBr disc, cm⁻¹): 3257 (N-H Stretch), 2933 (Ar-H), 1542, 1455 (Ar=C=C Stretch), 1650 (C=O Stretch), 1227 (C-N stretch), 1102 (C-Cl stretch), 1068 (C-O-C stretch); ¹H NMR (400 MHz, DMSO-D₆) 5.4 (d, 1H, pyrimidine CH), 5.9 (d, 1H,pyrimidine C=CH), 8.9 (t, H, C-NH-C, pyrimidine), 4.9 (d, 2H, N-CH₂-N), 5.2 (s, 1H, Pyrimidine N-H), 7.0-7.6 (m, 9H, Ar-H), 7.9 (d, 1H, triazole CH), 8.2 (d, 1H, triazole NH); LC-MS: m/z 412.0 [M⁺]+.

5.7 N-[[4,6-diphenyl-1,2,3,4-tetrahydropyrimidin-2-yl]oxy]methyl]-1H-1,2,4-triazol-3-amine (4a):
Yield: 45%; mp: 315-7°C; IR (KBr disc, cm⁻¹): 3057 (N-H Stretch), 2848 (Ar-H), 1576 (Aromatic C=C Stretch), 1662 (C-O Stretch), 3025 (Ar-H). 1218 (C-N Stretch); ¹H NMR (400 MHz, DMSO-D₆) 4.9 (d,1H, pyrimidine CH), 5.9 (d,1H,pyrimidine C=CH), 8.9 (t, H, C-NH-C, pyrimidine), 4.9 (d, 2H, N-CH₂-N), 5.2-5.3 (s, 1H, Pyrimidine N-H), 6.8-7.6 (m, 10H, Ar-H), 7.9 (d,1H, triazole CH), 8.1 (d, 1H, triazole NH); LC-MS: m/z 347.0 [M⁺]+.

5.8 N-[[4-(4-chlorophenyl)-6-phenyl-1,2,3,4-tetrahydropyrimidin-2-yl]oxy]methyl]-1H-1,2,4-triazol-3-amine (4b)
Yield: 49%; mp: 310-12°C; IR (KBr disc, cm⁻¹): 3052 (N-H Stretch), 2850 (Ar-H), 1569 (Aromatic C=C Stretch), 1666 (C-O Stretch), 3035 (Ar-H). 1222 (C-N Stretch), 1099 (C-Cl stretch); ¹H NMR (400 MHz, DMSO-D₆) δ 4.9 (d,1H, pyrimidine CH), 5.9 (d,1H,pyrimidine C=CH), 8.9 (t, H, C-NH-C, pyrimidine), 4.9 (d, 2H, N-CH₂-N), 5.2-5.3 (s, 1H, Pyrimidine N-H), 7.0-7.6 (m, 5H, Ar-H), 7.5-7.6 (m, 2H, Ar-H), 7.4-7.5 (m,2H,Ar-H), 7.8-7.9 (d,1H, triazole CH), 7.9-8.0 (d,1H,triazole NH); LC-MS: m/z 382.0 [M⁺]+.

5.9 [4-(4-Methoxy-phenyl)-6-phenyl-1,2,3,4-tetrahydro-pyrimidin-2-yl]oxy]methyl]-1H-[1,2,4]triazol-3-yl)-amine (4c) C₂₀H₂₀N₅O₂
Yield: 42%; mp: 325-7°C; IR (KBr disc, cm⁻¹): 3044 (N-H Stretch), 2839 (Ar-H), 1567 (Aromatic C=C Stretch), 1658 (C-O Stretch), 3055 (Ar-H), 1228 (C-N Stretch), 1252, 1100 (C-O-C stretch); ¹H NMR (400 MHz, DMSO-D₆) 4.9 (d,1H, pyrimidine CH), 5.9 (d,1H,pyrimidine C=CH), 8.9 (t, H, C-NH-C, pyrimidine), 4.9 (d, 2H, N-CH₂-N), 5.2-5.3 (s, 1H, Pyrimidine N-H), 7.0-7.6 (m, 9H, Ar-H), 3.4-3.5 (s, 3H, OCH₃), 7.8-7.9 (d,1H, triazole CH), 7.9-8.0 (d,1H,triazole NH); LC-MS: m/z 377.0 [M⁺]+.

5.10 N-[[6-(4-chlorophenyl)-4-phenyl-1,2,3,4-tetrahydro-pyrimidin-2-yl]oxy]methyl]-1H 1,2,4-triazol-3-amine (4d) C₁₉H₁₇ClN₅O:
Yield: 52%; mp: 310-2°C; IR (KBr disc, cm⁻¹): 3248 (N-H Stretch), 2920 (Ar-H), 1577, 1458 (Ar=C=C Stretch), 1639 (C-O Stretch), 1234 (C-N stretch), 3055 (Ar-H), 1070 (C-Cl stretch); ¹H NMR (400 MHz, DMSO-D₆) δ 5.8 (d,1H pyrimidine CH-Ar) 3.7 (d,1H,pyrimidine,C=CH) 4.8 (t, 1H, C-NH-C, triazole), 5.3 (d, 2H, O-CH₂-N), 3.4 (s, 1H, Pyrimidine N-H), 7.0-7.6 (m, 5H, Ar-H), 7.8 (m, 2H, Ar-H), 7.9 (m,2H,Ar-H), 7.2 (d,1H, triazole CH), 7.9-8.0 (d,1H,triazole -NH); LC-MS: m/z 382.0 [M⁺]+.

5.11 [4,6-Bis-(4-chloro-phenyl)-1,2,3,4-tetrahydro-pyrimidin-2-yl]oxy]methyl]-1H-[1,2,4] triazol-3-yl)-amine (4e) C₁₇H₁₆Cl₂N₆O
Yield:46%; mp: 318-20°C; IR (KBr disc, cm⁻¹): 3044 (N-H Stretch), 2839 (Ar-H), 1567 (Aromatic C=C Stretch), 1658 (C-O Stretch), 3055 (Ar-H), 1228 (C-N Stretch), 1086 (C-Cl stretch); ¹H NMR (400 MHz, DMSO-D₆) δ 5.7 (d,1H pyrimidine CH), 5.4 (d,1H,pyrimidine,C=CH) 4.9 (t, 1H, C-NH-C), 5.3 (d, 2H, O-CH₂-N), 5.2 (s, 1H, Pyrimidine N-H), 7.0-7.6 (m, 8H, Ar-H), 7.9 (d,1H, triazole CH), 8.2 (d,1H,triazole NH); LC-MS: m/z 416.0 [M⁺]+.

5.12 [6-(4-Chloro-phenyl)-4-(4-methoxy-phenyl)-1,2,3,4-tetrahydro-pyrimidin-2-yl]oxy]methyl]-1H-[1,2,4] triazol-3-yl)-amine (4f) C₂₀H₁₈ClN₅O₂
Yield: 45%; mp: 328-30°C; IR (KBr disc, cm⁻¹): 3034 (N-H Stretch), 2842 (Ar-H), 1568 (Aromatic C=C Stretch), 1659 (C-O Stretch), 3048 (Ar-H), 1232 (C-N Stretch), 1245, 1095 (C-O-C stretch), 1083 (C-Cl stretch); ¹H NMR (400 MHz, DMSO-D₆) δ 5.3 (d,1H pyrimidine CH-Ar) 4.9 (d,1H,pyrimidine,C=CH) 5.3 (3H, OCH₃), 4.8-4.9 (t, H, C-NH-C,trieazole), 5.1 (d, 2H,CH₂-N), 4.8 (s, 1H, Pyrimidine N-H), 7.0-7.6 (m, 8H, Ar-H), 7.8-7.9 (d,1H, triazole CH), 7.9-8.0 (d,1H,triazole NH); LC-MS: m/z 412.0 [M⁺]+.
NMR Spectra: 3a
6. Conclusion
In the present work, new dihydropyrimidine derivatives of N (3a-3f) and O (4a-4f) - manich derivatives of dihydropyrimidine were designed, synthesised, characterized and investigated for their inhibitory activity and cell cycle analysis in human breast cancer (MCF-7&MDA-MB-231) cell lines. Among these compounds 3c and 4b found with cell cycle arrest in G2-M phase. The apoptosis assay also revealed the compounds of chloro substitution (3c & 4b) were having more potent with 74% inhibition. These were comparable with standard drug tamoxifen.

Acknowledgements
AR acknowledges for support of grants ICMR-NIN, Indian Council of Medical Research [ICMR], Government of India. SB and VV are Co-Investigators of the projects. SB has helped in synthesis of dihydropyrimidine derivatives, GT and BP are assisted in carrying the work.

References


**Copyrights**

Copyright for this article is retained by the author(s), with first publication rights granted to the journal.

This is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).